Newleos Therapeutics
PrivateLast Round
Series A
Feb 13, 2025
Total Funding Raised
$93.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Newleos Therapeutics is a clinical-stage biotechnology company that develops oral small-molecule therapies for neuropsychiatric disorders including anxiety and substance use disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Newleos Therapeutics Comparables
Compare Newleos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Engrail Therapeutics | 88% | |
| Delix Therapeutics | 81% | |
| Damona Pharmaceuticals | 80% |
Newleos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 13, 2025 |
Key People
Founding team and executive leadership
Newleos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DCVC Bio | Series A |
| Novo Holdings | Series A |
| Arkin Bio Capital | Series A |
| Longwood Fund | Series A |
| Goldman Sachs Alternatives | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2026
Grew 16% QoQ, from 25 to 29 employees.
- Oct 21, 2025
Timothy Noyes named new President and Chief Executive Officer.
Recent news
Latest coverage and updates
- hiresJul 28, 2026
Newleos Therapeutics, Inc. hired Rohan Palekar as Board Chairman on Jul 28th '26.
Newleos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Newleos Therapeutics's valuation, stock price, and market status.
Is Newleos Therapeutics a public or private company?
Newleos Therapeutics is a private company.
What is the current stock price of Newleos Therapeutics?
Newleos Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Newleos Therapeutics worth (valuation)?
Valuation information for Newleos Therapeutics is not publicly available.
Can I buy Newleos Therapeutics stock?
Newleos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Newleos Therapeutics's last funding round?
Newleos Therapeutics's most recent funding round was Series A on February 13, 2025.
Who are the main investors in Newleos Therapeutics?
Key investors in Newleos Therapeutics include Goldman Sachs Alternatives.
Will Newleos Therapeutics IPO soon?
No public IPO plans have been announced for Newleos Therapeutics.
How can I track Newleos Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Newleos Therapeutics's secondary market activity and sign up for updates.